These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 26433782)

  • 1. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
    Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
    J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.
    Chilton CH; Crowther GS; Baines SD; Todhunter SL; Freeman J; Locher HH; Athanasiou A; Wilcox MH
    J Antimicrob Chemother; 2014 Mar; 69(3):697-705. PubMed ID: 24128668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.
    Louie T; Nord CE; Talbot GH; Wilcox M; Gerding DN; Buitrago M; Kracker H; Charef P; Cornely OA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6266-73. PubMed ID: 26248357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
    Gerding DN; Cornely OA; Grill S; Kracker H; Marrast AC; Nord CE; Talbot GH; Buitrago M; Gheorghe Diaconescu I; Murta de Oliveira C; Preotescu L; Pullman J; Louie TJ; Wilcox MH
    Lancet Infect Dis; 2019 Mar; 19(3):265-274. PubMed ID: 30709665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile.
    Skinner K; Birchall S; Corbett D; Thommes P; Locher HH
    J Med Microbiol; 2018 Sep; 67(9):1402-1409. PubMed ID: 30052178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection.
    Gehin M; Desnica B; Dingemanse J
    Int J Antimicrob Agents; 2015 Nov; 46(5):576-81. PubMed ID: 26419191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
    Reigadas E; Alcalá L; Marín M; Pelaéz T; Martin A; Iglesias C; Bouza E
    J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden.
    Rashid MU; Lozano HM; Weintraub A; Nord CE
    Anaerobe; 2013 Apr; 20():32-5. PubMed ID: 23454525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of MCB3681 against Clostridium difficile strains.
    Rashid MU; Dalhoff A; Weintraub A; Nord CE
    Anaerobe; 2014 Aug; 28():216-9. PubMed ID: 25016084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14.
    Knight DR; Giglio S; Huntington PG; Korman TM; Kotsanas D; Moore CV; Paterson DL; Prendergast L; Huber CA; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV
    J Antimicrob Chemother; 2015 Nov; 70(11):2992-9. PubMed ID: 26221017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
    Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
    J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
    Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012.
    Lachowicz D; Pituch H; Obuch-Woszczatyński P
    Anaerobe; 2015 Feb; 31():37-41. PubMed ID: 25242196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
    Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
    J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two Clusters of Fluoroquinolone and Clindamycin-Resistant Clostridium difficile PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis.
    Nyc O; Tejkalova R; Kriz Z; Ruzicka F; Kubicek L; Matejkova J; Kuijper E; Krutova M
    Microb Drug Resist; 2017 Jul; 23(5):609-615. PubMed ID: 27860531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
    Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cadazolid for the treatment of Clostridium difficile.
    Endres BT; Bassères E; Alam MJ; Garey KW
    Expert Opin Investig Drugs; 2017 Apr; 26(4):509-514. PubMed ID: 28286992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
    Poilane I; Fantinato C; Cruaud P; Collignon A
    Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.